Cargando…

Novel oligodeoxynucleotide agonists of TLR9 containing N(3)-Me-dC or N(1)-Me-dG modifications

Synthetic oligodeoxynucleotides containing unmethylated CpG motifs activate Toll-Like Receptor 9 (TLR9). Our previous studies have shown the role of hydrogen-bond donor and acceptor groups of cytosine and guanine in the CpG motif and identified synthetic immunostimulatory motifs. In the present stud...

Descripción completa

Detalles Bibliográficos
Autores principales: Putta, Mallikarjuna Reddy, Zhu, FuGang, Li, Yukui, Bhagat, Lakshmi, Cong, YanPing, Kandimalla, Ekambar R., Agrawal, Sudhir
Formato: Texto
Lenguaje:English
Publicado: Oxford University Press 2006
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1904100/
https://www.ncbi.nlm.nih.gov/pubmed/16798912
http://dx.doi.org/10.1093/nar/gkl430
_version_ 1782133961329213440
author Putta, Mallikarjuna Reddy
Zhu, FuGang
Li, Yukui
Bhagat, Lakshmi
Cong, YanPing
Kandimalla, Ekambar R.
Agrawal, Sudhir
author_facet Putta, Mallikarjuna Reddy
Zhu, FuGang
Li, Yukui
Bhagat, Lakshmi
Cong, YanPing
Kandimalla, Ekambar R.
Agrawal, Sudhir
author_sort Putta, Mallikarjuna Reddy
collection PubMed
description Synthetic oligodeoxynucleotides containing unmethylated CpG motifs activate Toll-Like Receptor 9 (TLR9). Our previous studies have shown the role of hydrogen-bond donor and acceptor groups of cytosine and guanine in the CpG motif and identified synthetic immunostimulatory motifs. In the present study to elucidate the significance of N3-position of cytosine and N1-position of guanine in the CpG motif, we substituted C or G of a CpG dinucleotide with N(3)-Me-cytosine or N(1)-Me-guanine, respectively, in immunomodulatory oligodeoxynucleotides (IMOs). IMOs containing N-Me-cytosine or N-Me-guanine in C- or G-position, respectively, of the CpG dinucleotide showed activation of HEK293 cells expressing TLR9, but not TLR3, 7 or 8. IMOs containing N-Me-cytosine or N-Me-guanine modification showed activity in mouse spleen cell cultures, in vivo in mice, and in human cell cultures. In addition, IMOs containing N-Me-substitutions reversed antigen-induced Th2 immune responses towards a Th1-type in OVA-sensitized mouse spleen cell cultures. These studies suggest that TLR9 tolerates a methyl group at N1-position of G and a methyl group at N3-position of C may interfere with TLR9 activation to some extent. These are the first studies elucidating the role of N3-position of cytosine and N1-position of guanine in a CpG motif for TLR9 activation and immune stimulation.
format Text
id pubmed-1904100
institution National Center for Biotechnology Information
language English
publishDate 2006
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-19041002007-06-28 Novel oligodeoxynucleotide agonists of TLR9 containing N(3)-Me-dC or N(1)-Me-dG modifications Putta, Mallikarjuna Reddy Zhu, FuGang Li, Yukui Bhagat, Lakshmi Cong, YanPing Kandimalla, Ekambar R. Agrawal, Sudhir Nucleic Acids Res Article Synthetic oligodeoxynucleotides containing unmethylated CpG motifs activate Toll-Like Receptor 9 (TLR9). Our previous studies have shown the role of hydrogen-bond donor and acceptor groups of cytosine and guanine in the CpG motif and identified synthetic immunostimulatory motifs. In the present study to elucidate the significance of N3-position of cytosine and N1-position of guanine in the CpG motif, we substituted C or G of a CpG dinucleotide with N(3)-Me-cytosine or N(1)-Me-guanine, respectively, in immunomodulatory oligodeoxynucleotides (IMOs). IMOs containing N-Me-cytosine or N-Me-guanine in C- or G-position, respectively, of the CpG dinucleotide showed activation of HEK293 cells expressing TLR9, but not TLR3, 7 or 8. IMOs containing N-Me-cytosine or N-Me-guanine modification showed activity in mouse spleen cell cultures, in vivo in mice, and in human cell cultures. In addition, IMOs containing N-Me-substitutions reversed antigen-induced Th2 immune responses towards a Th1-type in OVA-sensitized mouse spleen cell cultures. These studies suggest that TLR9 tolerates a methyl group at N1-position of G and a methyl group at N3-position of C may interfere with TLR9 activation to some extent. These are the first studies elucidating the role of N3-position of cytosine and N1-position of guanine in a CpG motif for TLR9 activation and immune stimulation. Oxford University Press 2006 2006-06-23 /pmc/articles/PMC1904100/ /pubmed/16798912 http://dx.doi.org/10.1093/nar/gkl430 Text en © 2006 The Author(s)
spellingShingle Article
Putta, Mallikarjuna Reddy
Zhu, FuGang
Li, Yukui
Bhagat, Lakshmi
Cong, YanPing
Kandimalla, Ekambar R.
Agrawal, Sudhir
Novel oligodeoxynucleotide agonists of TLR9 containing N(3)-Me-dC or N(1)-Me-dG modifications
title Novel oligodeoxynucleotide agonists of TLR9 containing N(3)-Me-dC or N(1)-Me-dG modifications
title_full Novel oligodeoxynucleotide agonists of TLR9 containing N(3)-Me-dC or N(1)-Me-dG modifications
title_fullStr Novel oligodeoxynucleotide agonists of TLR9 containing N(3)-Me-dC or N(1)-Me-dG modifications
title_full_unstemmed Novel oligodeoxynucleotide agonists of TLR9 containing N(3)-Me-dC or N(1)-Me-dG modifications
title_short Novel oligodeoxynucleotide agonists of TLR9 containing N(3)-Me-dC or N(1)-Me-dG modifications
title_sort novel oligodeoxynucleotide agonists of tlr9 containing n(3)-me-dc or n(1)-me-dg modifications
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1904100/
https://www.ncbi.nlm.nih.gov/pubmed/16798912
http://dx.doi.org/10.1093/nar/gkl430
work_keys_str_mv AT puttamallikarjunareddy noveloligodeoxynucleotideagonistsoftlr9containingn3medcorn1medgmodifications
AT zhufugang noveloligodeoxynucleotideagonistsoftlr9containingn3medcorn1medgmodifications
AT liyukui noveloligodeoxynucleotideagonistsoftlr9containingn3medcorn1medgmodifications
AT bhagatlakshmi noveloligodeoxynucleotideagonistsoftlr9containingn3medcorn1medgmodifications
AT congyanping noveloligodeoxynucleotideagonistsoftlr9containingn3medcorn1medgmodifications
AT kandimallaekambarr noveloligodeoxynucleotideagonistsoftlr9containingn3medcorn1medgmodifications
AT agrawalsudhir noveloligodeoxynucleotideagonistsoftlr9containingn3medcorn1medgmodifications